Chronic heart failure (CHF) is a significant public health issue for the entire world, since it is a very common disease that sometimes leads to life-threatening illness and has a high risk and mortality rate . Our aim is to look at what has been accomplished in recent years in the care of CHF patients with a left ventricular ejection fraction (LVEF) of less than 40%. BNP has recently been discovered to be essential in the pathogenesis of heart disease. As a result, we attempted to examine the outcomes of a complex medical treatment procedure in CHF patients using a combination of sacubitril and valsartan, which is an angiotensin receptor neprilysin inhibitor. The system treatment methods used in the treatment of these patients, especially cardiac resynchronization therapy, were also investigated (CRT). Finally, we compared the outcomes of a complex medical treatment procedure using a combination of sacubitril and valsartan, which is an angiotensin receptor neprilysin inhibitor, to those of cardiac resynchronization therapy. Patients who are handled in this manner (with CRT) are forced to stop working, even if only for a short time. Furthermore, CRTs are much more costly than traditional medicine.
Author (s) Details
Eyubova Ulviyya Aladdin
Department of III Internal Diseases, Azerbaijan Medical University, Baku, Azerbaijan.
View Book :- https://stm.bookpi.org/HMMR-V8/article/view/818